Cytokinetics’ long and winding road to develop its lead heart drug will face an adcomm this fall

The path Cytokinetics has plotted for its lead heart drug will face one more potential obstacle as it approaches its PDUFA date this fall — an adcomm.

FDA told Cytokinetics it plans to convene its panel of experts to discuss the application for omecamtiv mecarbil, the biotech said Tuesday morning....

Click to view original post